Xenon Pharmaceuticals
XENE
XENE
180 hedge funds and large institutions have $2.1B invested in Xenon Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 71 increasing their positions, 50 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
0.84% less ownership
Funds ownership: 96.48% → 95.63% (-0.84%)
11% less capital invested
Capital invested by funds: $2.36B → $2.1B (-$264M)
43% less call options, than puts
Call options by funds: $10.9M | Put options by funds: $19.2M
Holders
180
Holding in Top 10
9
Calls
$10.9M
Puts
$19.2M
Top Buyers
| 1 | +$34.8M | |
| 2 | +$33.4M | |
| 3 | +$23.1M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$17.2M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$12.3M |
Top Sellers
| 1 | -$32M | |
| 2 | -$27.6M | |
| 3 | -$23.9M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$20.7M |
| 5 |
Holocene Advisors
New York
|
-$18.2M |